All In Biotech

NDA 216482 · Azurity

Myhibbin

Mycophenolate Mofetil · Oral

Last checked: Nov 19, 2026Latest source record: Jul 29, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

May 1, 2024

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,151

212 Phase 3, 106 recruiting

FAERS reports

106,242

99,414 serious, 20,488 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: EMBRYOFETAL TOXICITY, MALIGNANCIES, and SERIOUS INFECTIONS Use during pregnancy is associated with increased risks of first trimester pregnancy loss and congenital malformations. Avoid if safer treatment options are available. Females of reproductive potential must be counseled regarding pregnancy prevention and planning [see Warnings and Precautions ( 5.1 ), Use in Special Populations ( 8.1 , 8.3 )] . Increased risk of development of lymphoma and other malignancies, particularly of the skin [see Warnings and Precautions ( 5.2 )] . Increased susceptibility to bacterial, viral, fungal and protozoal infections, including opportunistic infections and viral reactivation of hepatitis B and C, which may lead to hospitalizations and fatal outcomes [see Warnings and Precautions ( 5.3 )] . WARNING: EMBRYOFETAL TOXICITY, MALIGNANCIES and SERIOUS INFECTIONS See full prescribing...

What it is approved for

From the label in effect Jul 31, 2026.

MYHIBBIN is indicated for the prophylaxis of organ rejection, in adult and pediatric recipients 3 months of age and older of allogeneic kidney [see Clinical Studies ( 14.1 )], heart [see Clinical Studies ( 14.2 )] or liver transplants [see Clinical Studies ( 14.3 )] , in combination with other immunosuppressants. MYHIBBIN is an antimetabolite immunosuppressant indicated for the prophylaxis of organ rejection in adult and pediatric recipients 3 months of age and older of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants. ( 1 )

Mechanism: Mycophenolate mofetil (MMF) is absorbed following oral administration and hydrolyzed to mycophenolic acid (MPA), the active metabolite. MPA is a selective uncompetitive inhibitor of the two isoforms (type I and type II) of inosine monophosphate dehydrogenase (IMPDH) leading to inhibition of the de novo pathway of guanosine nucleotide synthesis and blocks DNA synthesis. The mechanism of action of MPA is multifaceted and includes effects on cellular checkpoints responsible for metabolic programming of lymphocytes. MPA shifts transcriptional activities in lymphocytes from a proliferative state...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 1, 2024 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
1 products under this application
  • MYHIBBIN · MYCOPHENOLATE MOFETIL 200MG/ML · SUSPENSION, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Mycophenolate Mofetil" as an intervention, any sponsor and status, largest first.

All 1,151 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use16,486
  • drug ineffective10,406
  • product use in unapproved indication7,029
  • diarrhoea5,216
  • pyrexia4,594
  • cytomegalovirus infection4,470
  • pneumonia4,405
  • condition aggravated3,948
  • transplant rejection3,569
  • infection3,508
  • fatigue3,430
  • nausea3,309

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004264
2005312
2006586
2007750
20081,013
20091,546
20101,368
20111,579
20121,528
20131,511
20141,774
20152,127
20162,666
20174,368
20186,301
20198,404
20209,582
20219,117
20228,343
20239,669
202412,352
202512,320
20268,757

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Myhibbin (Mycophenolate Mofetil)

2024 spending

$13K

Beneficiaries

n/a

15 claims

Per beneficiary

n/a

$4.10 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$12,698

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,999 on PubMed

Sponsor: Azurity

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.